



This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (Currently amended) A compound of the following formula (I):



wherein

P^1 and P^2 independently represent a polyethylene glycol (PEG) moiety;

Z^1 and Z^2 independently represent a polyclonal, monoclonal, multi-valent, multi-specific, humanized or chimeric antibody, a single chain antibody, a Fab fragment, a Fab' or F(ab')₂ fragment, or an epitope-binding fragment thereof;

X^1 and X^2 independently represent N;

A^1 and A^2 independently represent -NHCO-;

B^1 and B^2 independently represent -CO-;

V^1 and V^2 independently represent a covalent bond;

W^1 and W^2 independently represent $-(CH_2)_w-$;

Y^1 and Y^2 independently represent $-(CH_2)_y-$;

L^1 and L^2 independently represent a maleimide moiety residue, each of which is covalently linked to Z^1 and Z^2 , respectively, and each of which is covalently linked through the maleimide nitrogen atom to Y^1 and Y^2 , respectively;

M^1 represents $-(CH_2)_m-$;

~~n is zero;~~



w is 1 or 2;

y is 1, 2, 3, 4, 5 or 6; and

m is 2.

2. (previously presented) A compound as claimed in claim 1 wherein Z^1 and Z^2 independently represent a whole antibody or a functionally active antibody fragment or derivative.

3. (currently amended) A compound of the following formula (III):



wherein

P¹ and P² independently represent a polyethylene glycol (PEG) moiety;

X¹ and X² independently represent ϕ or N;

A¹ and A² independently represent -NHCO-;

B¹ and B² independently represent -CO-;

V¹ and V² independently represent a covalent bond;

W¹ and W² independently represent -(CH₂)_w-;

Y¹ and Y² independently represent -(CH₂)_y-;

M¹ represents -(CH₂)_m-;

~~n is zero;~~

w is 1 or 2;

y is 1, 2, 3, 4, 5 or 6; and

m is 2 .

4. (cancelled))

5. (cancelled)

6. (cancelled)

7. (cancelled)

8. (previously presented) A compound as claimed in claim 1 that is

DiFab'-conjugated 3-maleimidyl-N-(2-{[3-maleimidyl-propionyl]-[(2-(methoxy-polyethoxy)-ethylcarbamoyl)-methyl]-amino}-ethyl)-N-[(2-(methoxy-polyethoxy)-ethylcarbamoyl)-methyl]-propionamide; or

DiFab'-conjugated 3-maleimidyl-N-(2-{[3-(maleimidyl)-propionyl]-[2-(2-(methoxy-polyethoxy)-ethylcarbamoyl)-ethyl]-amino}-ethyl)-N-[2-(2-(methoxy-polyethoxy)-ethylcarbamoyl)-ethyl]-propionamide.

9. (currently amended) A compound as claimed in claim ~~[[4]]~~ 3 that is

3-Maleimidyl-N-(2-{[3-maleimidyl-propionyl]-[(2-(methoxy-polyethoxy)-ethylcarbamoyl)-methyl]-amino}-ethyl)-N-[(2-(methoxy-polyethoxy)-ethylcarbamoyl)-methyl]-propionamide; or

3-Maleimidyl-N-(2-{[3-(maleimidyl)-propionyl]-[2-(2-(methoxy-polyethoxy)-ethylcarbamoyl)-ethyl]-amino}-ethyl)-N-[2-(2-(methoxy-polyethoxy)-ethylcarbamoyl)-ethyl]-propionamide.

10. (previously presented) A pharmaceutical composition comprising a compound as claimed in claim 1 in association with one or more pharmaceutically acceptable carriers, excipients or diluents.
11. (new) A pharmaceutical composition comprising a compound as claimed in claim 2 in association with one or more pharmaceutically acceptable carriers, excipients or diluents.
12. (new) A pharmaceutical composition comprising a compound as claimed in claim 8 in association with one or more pharmaceutically acceptable carriers, excipients or diluents.